CN110819630B - 环状RNA circ-01477及其应用 - Google Patents
环状RNA circ-01477及其应用 Download PDFInfo
- Publication number
- CN110819630B CN110819630B CN201911026232.3A CN201911026232A CN110819630B CN 110819630 B CN110819630 B CN 110819630B CN 201911026232 A CN201911026232 A CN 201911026232A CN 110819630 B CN110819630 B CN 110819630B
- Authority
- CN
- China
- Prior art keywords
- circ
- sirna
- expression
- circular rna
- spinal cord
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091028075 Circular RNA Proteins 0.000 title claims abstract description 15
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 30
- 208000020431 spinal cord injury Diseases 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 108091081021 Sense strand Proteins 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 abstract description 23
- 230000008929 regeneration Effects 0.000 abstract description 8
- 238000011069 regeneration method Methods 0.000 abstract description 8
- 208000028389 Nerve injury Diseases 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 7
- 230000008764 nerve damage Effects 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000005012 migration Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 208000001738 Nervous System Trauma Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 208000028412 nervous system injury Diseases 0.000 abstract description 2
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 210000000278 spinal cord Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061431 Glial scar Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000008522 astrocyte cell migration Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种环状RNA circ‑01477及其在制备促进神经再生和修复神经损伤药物中的应用。研究结果表明通过下调或者抑制机体circ‑01477的表达,抑制星形胶质细胞的增殖和迁移,进而有利于中枢神经损伤修复。
Description
技术领域
本发明属于神经再生和修复技术领域,具体涉及一种环状RNA circ-01477在制备促进神经再生和修复神经损伤药物中的应用。
背景技术
脊髓损伤是神经损伤中比较严重的一类,会导致永久的运动和感觉失常,影响人们生活质量。脊髓损伤后机体会发生一系列细胞和分子水平上的变化,涉及多种细胞,包括星形胶质细胞、少突细胞、小胶质细胞、血管内皮细胞等,影响轴突损伤后的再生微环境。其中星形胶质细胞在脊髓损伤后增生,进而在损伤处形成胶质疤痕,阻碍轴突再生和神经环路重塑。此外,胶质疤痕也可以限制炎症反应扩散到周围组织,修复受损的血脑屏障,维持局部微环境。因此星形胶质细胞在脊髓损伤后发挥着重要的作用。
环状RNA circular RNAs(circRNAs)是一类不具有5'末端帽子和3'末端poly(A)尾巴、并以共价键形成环形结构的RNA.,可以调节基因表达,参与多种生物学过程。目前关于circRNAs的研究主要集中在癌症方面。在神经系统发育中circRNAs也发挥着重要的作用,可以影响神经元的迁移和轴突生长。但到目前为止circRNAs在中枢神经系统损伤修复中的作用鲜有报道,尤其是对星形胶质细胞的表型调节。
发明内容
本发明目的在于提供一种新的大鼠源的环状RNA circ-01477及其用途,可用于制备促进神经再生和修复神经损伤药物。
本发明具体技术方案如下:
一种环状RNA circ-01477,所述circRNA的cDNA核苷酸序列如SEQ ID NO:1所示,首尾连接成环状结构。
本发明另一目的在于提供上述环状RNA circ-01477在制备促进神经再生和修复神经损伤药物中的应用,所述神经损伤为中枢神经系统脊髓损伤。
可根据circ-01477核苷酸序列设计干预circ-01477表达的物质,选自化合物、蛋白、多肽、多糖、糖蛋白、糖肽、核酸中的一种或几种。
优选的,所述干预circRNA表达的物质,选自与circ-01477环化位点处的序列互补的siRNA。
本发明另一目的在于提供一种干预上述circ-01477表达的siRNA,核苷酸序列如下:
circ-01477 siRNA正义链:5’-cgaggggcuacacuugcca dTdT-3’(SEQ ID NO:4)。
circ-01477 siRNA反义链:5’-uggcaaguguagccccucg dTdT-3’(SEQ ID NO:5)。
本发明研究结果表明,所述siRNA能够干扰circ-01477的表达,抑制星形胶质细胞增殖和迁移。
本发明另一目的在于提供上述干预circ-01477表达的siRNA在制备促进神经再生和修复神经损伤药物中的应用。
本发明构建大鼠脊髓损伤半切模型,取损伤不同时间点的脊髓组织,通过RNA-seq及生物信息学分析,挑选损伤后表达变化明显的circRNAs。针对筛选到的circRNAs设计特异性的背向引物,再通过PCR验证以及测序鉴定,获得一种新的环状RNA circ-01477。在原代星形胶质细胞中,设计siRNA干扰circ-01477的表达,可以抑制星形胶质细胞增殖和迁移。
附图说明
图1为实施例1所述circ-01477在大鼠脊髓损伤后脊髓组织中不同时间点的表达变化(以GAPDH为内参)。
图2为实施例2所述circ-01477的siRNA对原代星形胶质细胞中circ-01477表达的影响(以GAPDH为内参)。
图3为实施例2所述circ-01477的siRNA干扰circ-01477对星形胶质细胞增殖(A)和迁移(B)的影响。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。
在本发明中所使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例并参照数据进一步详细描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1:circ-01477的表达与鉴定
对SD(Sprague Dawley)大鼠脊髓半切损伤后不同时间点(0d、1d、3d、7d、14d、21d和28d)的脊髓组织进行RNA-seq。根据测序结果挑选全部由外显子组成且环>500nt的表达差异明显的circRNAs。测序结果分析筛选出来的circRNA,进一步通过PCR验证circRNA的存在。根据circRNAs引物设计原则对这些circRNAs设计背向引物,每个circRNA使用NCBI设计引物。根据引物信息选择不同的退火温度进行PCR扩增,再通过琼脂糖凝胶电泳选出条带大小与预期相符的circRNAs,送公司测序,并将测序结果与原始序列比对验证其是否跨越环化位点。最终得到与预期条带大小一致且测序鉴定过环化位点的circRNAs,并挑选其中的circ-01477进行进一步研究,circ-01477的cDNA序列如SEQ ID NO:1所示。
一、脊髓组织RNA提取
取鼠脊髓T 9半切损伤后不同时间点(0d、1d、3d、7d、14d、21d和28d)的损伤处近端5mm脊髓组织按Reagent(Invitrogen)说明书提取组织RNA。大鼠脊髓损伤后不同时间点的损伤组织放入1.5ml RNase-free EP管,加入1mlReagent(Invitrogen);将EP管置于冰中并使用电动匀浆器将组织匀浆,冰上静置5min-10min裂解。加入三氯甲烷200μl,涡旋剧烈振荡20s,室温静置10min;13000rpm,4℃离心15min。小心仔细吸取上清,加入异丙醇800μl,上下颠倒轻柔混匀,-20℃静置1h,13000rpm,4℃离心15min,弃除上清。加入1ml 75%乙醇,轻轻洗涤沉淀,4℃离心13000rpm,5min;去除上清,吹干。加入适量RNase-free H2O,65℃促溶10min;检测RNA的OD值及浓度,-80℃保存备用。
二、RNA逆转录合成cDNA
使用逆转录试剂盒(Takara RR037A),将500 ng的RNA逆转录为cDNA。
(1)circRNA的逆转
冰上操作,每个反应体系10μl,如下:
(2)mRNA的逆转
冰上操作,每个反应体系10μl,如下:
反应程序为:37℃45min,85℃5min,4℃∞。
三、qRT-PCR
根据circRNAs引物设计原则设计circRNAs qRT-PCR引物序列。
circ-01477qRT-PCR引物
circ-01477-F 5’-gaatgtcacaagcagatgagaga-3’(SEQ ID NO:2)
circ-01477-R 5’-ctttgcatcaagacttgtggg-3’(SEQ ID NO:3)
将逆转录反应得到的cDNA,按照1∶10稀释,进行如下qRT-PCR反应。
(1)按下列组份配制qRT-PCR反应液:
(2)反应液混匀,Real-time PCR仪反应程序如下:
(3)反应设置3个复孔,内参为GAPDH,程序结束后,查看溶解曲线与扩增曲线,舍去误差较大的实验数据,根据具体实验要求,对数据进行统计分析。
(4)考察上述circRNA在大鼠脊髓损伤后受损脊髓组织中不同时间点的表达变化,结果如图1所示,表明circ-01477在脊髓损伤后表达持续下降。
实施例2:circRNA的功能验证
一、原代星形胶质细胞的培养
将出生后1天的红皮鼠脊髓分离,移入一盛有分离缓冲液(DMEM)的培养皿中。体视镜下剥离脊膜分离出脊髓,移入另一盛有分离缓冲液(DMEM)的培养皿中。使用分离缓冲液(DMEM/F12)清洗组织,用手术剪将组织剪碎。加入消化液0.25%胰酶2ml,37℃消化15min,每5min中晃动几次。使用消化终止液(DMEM/F12+10%FBS)终止消化,1000rpm离心5min,弃去上清。加入完全培养基(DMEM/F12+10%FBS+1%p.s+1%L-glu)重悬细胞。镜检观察神经细胞结团情况,过细胞筛网,收集细胞悬液。计数后种在100mm培养皿中,每2-3天换液一次。
二、星形胶质细胞转染
将培养至P1代的星形胶质细胞用0.25%胰酶进行消化,加入完全培养基(DMEM/F12+10%FBS+1%p.s+1%L-glu)终止消化,计数。将一定量的细胞与siRNA混合,充分混匀,使其最终浓度达到每管100μl混合液中含有2×106星胶细胞+200nM的siRNA,其中细胞体积为90μl,siRNA体积为10μl。然后参照NEPA21(NEPAGENE公司)原代神经细胞电转染操作步骤进行电转。
circ-01477 siRNA如下所示:
circ-01477 siRNA正义链:5’-cgaggggcuacacuugcca dTdT-3’(SEQ ID NO:4)。
circ-01477 siRNA反义链:5’-uggcaaguguagccccucg dTdT-3’(SEQ ID NO:5)。
三、星形胶质细胞RNA提取、逆转录及qRT-PCR
原代星形胶质细胞分别转染特异性针对circ-01477 siRNA及其对照siRNANegative Control(NC),24h或48h后,收细胞,按Reagent(Invitrogen)说明书提取星形胶质细胞RNA,逆转录,进行qRT-PCR,方法同实施例1中所述。结果如图2所示,siRNA处理24h或48h后,circ-01477 siRNA可以显著干扰circ-01477在星形胶质细胞中的表达,**P<0.01。
四、Edu细胞增殖实验
原代星形胶质细胞分别转染特异性针对circ-01477的siRNA(circ-01477 siRNA)及其对照(NC),24h后,根据Cell-LightTM EdUIn Vitro Kit(广州市锐博生物科技有限公司,C10310-1)进行Edu细胞增殖实验。按1000:1的比例用完全培养基稀释EdUA溶液;加入96孔板,37℃孵育24h,弃去培养基;PBS轻柔清洗细胞1-2次。每孔加入4%多聚甲醛约100μl,室温孵育30min,弃去4%多聚甲醛;每孔加入2mg/ml甘氨酸50μl,孵育5min后,弃甘氨酸溶液;每孔加入PBS 100μl,5min后弃去PBS;每孔加入100μl渗透剂(0.5%TritonX-100的PBS),10min后弃去液体;PBS清洗1次,5min。每孔加入染色反应液约100μl,室温、避光、孵育30min后,弃除反应液;加入渗透剂(0.5%TritonX-100的PBS)100μl清洗2-3次,每次10min,弃除渗透剂;按100:1的比例用ddH2O稀释试剂F,制备1×Hoechst 33342反应液,避光保存;每孔加入1×Hoechst 33342反应液50μl,室温避光孵育30min后,弃反应液;每次每孔加入PBS 100μl清洗2-3次;每孔加入PBS 100μl荧光显微镜拍照。用circ-01477 siRNA与siRNA Negative Control(NC)转染原代培养的星形胶质细胞,在转染siRNA24h后,按上述方法进行EdU标记,Edu实验结果如图3A所示,柱状图为siRNA干扰circ-01477后星形胶质细胞的增殖率,*P<0.05。结果表明:与对照组相比,siRNA干扰circ-01477,显著抑制星形胶质细胞的增殖。
五、Transwell迁移实验
在超净台中,将需要检测的细胞板中的星形胶质细胞消化下来,用DMEM重悬,计数并调整为3×105/mL。每个Transwell中加入100μl不同组别的重悬细胞,之后将Transwell轻轻放到含有500μl完全培养基的24孔板的孔中,培养箱培养。培养24h后,取出Transwell,4%多聚甲醛/PBS固定0.5h,用0.1%结晶紫染色0.5h,水洗三遍,轻轻用棉签将没有穿过膜的细胞擦掉,晾干。倒置显微镜下观察,随机选取5个以上视野,拍照。实验重复3次以上,进行统计分析。结果如图3B所示,Transwell结果表明,与NC相比,circ-01477 siRNA干扰circ-01477,明显抑制星形胶质细胞迁移,右侧柱状图为siRNA干扰circ-01477后星形胶质细胞的迁移率,*P<0.05。
序列表
<110> 南通大学
<120> 环状RNA circ-01477及其应用
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2233
<212> DNA
<213> 大鼠(Rat)
<400> 1
tggctgccag ctccccacca gcaattccca aagtcagaat caaaacaatt aagacatcat 60
caggggaaat caaacggact gttacaaggg tcctgccaga ccctgatgac ccaagtgagt 120
cacctgcagg gggcacaagt gctgaggttc caagtgaggt gccaggggat gaaggttcag 180
ccatgcctgt ggaagagcac ttttctgagg caggcataga ttcagggagc ccccagggtg 240
acagaaaagg gggtgagaat atgatcaaca agaccagtga ctctttgtct ccctgccgca 300
cctctgggcc ccgggtccca aaaggatctg ccctgaactc acaggcaagc aagaagcaac 360
agagcacagc acttcaggca tcaactccgg cccctgccag tctcttgccg aaagctgtgc 420
acttggccaa cttgaacctg gtcccccaca gtgttgctgc ttctgtgact gccaagtctt 480
cagcacagag acggagccag cctcaggtca cgcaaatgac agtgcccctg gtccaccagg 540
tgaaaaaggc cgcccctcta attgtggagg tcttcaacaa ggtccttcac agctctaacc 600
ctgtgcccct ctatgcgcca aatctcagcc cacccgcaga cagcagaatc catgtgccgg 660
ccagtgggta ctgctgcctg gagtgtggag acgcgtttgc cttagagaag agcctgagcc 720
agcactacag ccggcggagt gtccacatcg aggtgctgtg cacactgtgc tctaagacac 780
tgctcttctt caacaagtgc agcctgcttc ggcatgcccg tgaccacaag agcaagggac 840
tcgtcatgca gtgttctcag ctgcttgtga agcccatctc tgcggaccag atgtttgtgg 900
cggctcctgt gaactccact gcaccagcaa ccccagctgc ttcttcctcc cccaaaccca 960
gccccacttt ggacaatgcc agccctgtaa ttccagcctt gccactttac ccagacccag 1020
tgaggctcat ccggtatgga accaaatgtc ctgaatgtca caagcagatg agagattata 1080
tggtcctggc tacacatttc cagaggacaa cagaggaaac cgaggggcta cacttgccag 1140
catccagcca tgggggatat gaaaacccca gattttgatg atcttctggc ggcctttgac 1200
atcccagatc ccacaagtct tgatgcaaag gaggccatcc agactcctag tgaggagaat 1260
gagagtcccc tgaagtcctc aggcatgtgc atggatgaga atgtgtcctt gtctcactca 1320
ggatcagtcc cagatgtgcc ggctgtgagt gtcattgtca agaacaccag ccgccaagag 1380
tcatttgaag cagagaaaga ccacattact cccagtctcc tacataatgg attccggggt 1440
tcagacctgc ccccagactc ccaccattgt ggaaagtttg attctacttt tataaatgga 1500
gacagtgcta ggagtttcac gagtaagcta gagccttcca agtcggagcc attacccacc 1560
ttcaaccagt tcagcccaat ctctagccca gaacctgagg atcctgtcaa agataatggg 1620
tttgggataa agtccaagca ctctgacagt tatttcccac ctcctcctgg gactgtggga 1680
ggcccagtcc tggaagctct ggcaaagttc ccagtcccag agctacacat gtttgatcac 1740
ttttgtaaga aagaacccaa accagaaccc ttgcctttag agagccagca ggagcatgaa 1800
cagggtgggc agaaggtggt ggagcctcac aaagatctgg attccagtcg gttctttggg 1860
gaagctttag agttcaatag tcaccctagc aacagtattg gagagcccaa gaagcttgtt 1920
ccagagctta gtgcttgctc ctctgtcccc cctaggcagc gtctgaaacc agctcattcc 1980
aagctatcct cttgtgttgc agccttggtg gccttacagg ccaaaagggt ggccaatgtc 2040
accaaggagg atcagcctgg tcacataaag gattcctcag ggcccactaa agagggttct 2100
aaaggcagcc ccaaaatgcc caagtcacca aagagtcccc ggagccctct agaggccact 2160
agaaaaaata tcaagccatc agatagccct cggagcatct gcagtgacag cagcagcaaa 2220
gggtcccctt ctg 2233
<210> 2
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gaatgtcaca agcagatgag aga 23
<210> 3
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ctttgcatca agacttgtgg g 21
<210> 4
<211> 21
<212> DNA/RNA
<213> 人工序列(Artificial Sequence)
<400> 4
cgaggggcua cacuugccat t 21
<210> 5
<211> 21
<212> DNA/RNA
<213> 人工序列(Artificial Sequence)
<400> 5
uggcaagugu agccccucgt t 21
Claims (2)
1.干预环状RNA circ-01477表达的 siRNA在制备修复脊髓损伤药物中的应用,其特征在于所述circ-01477的cDNA核苷酸序列如SEQ ID NO:1所示。
2.如权利要求1所述的应用,其特征在于所述干预环状RNA circ-01477表达的siRNA正义链核苷酸序列如SEQ ID NO:4所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911026232.3A CN110819630B (zh) | 2019-10-25 | 2019-10-25 | 环状RNA circ-01477及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911026232.3A CN110819630B (zh) | 2019-10-25 | 2019-10-25 | 环状RNA circ-01477及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110819630A CN110819630A (zh) | 2020-02-21 |
CN110819630B true CN110819630B (zh) | 2023-04-07 |
Family
ID=69550657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911026232.3A Active CN110819630B (zh) | 2019-10-25 | 2019-10-25 | 环状RNA circ-01477及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110819630B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113278690B (zh) * | 2021-05-08 | 2023-02-07 | 南通大学 | 环状RNA circ-26782在制备脊髓损伤诊疗药物中的应用 |
CN113528524B (zh) * | 2021-07-08 | 2023-03-17 | 四川大学 | 一种环状rna及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109897853A (zh) * | 2019-03-13 | 2019-06-18 | 南通大学 | 一种长链非编码rna及其应用 |
CN110141578A (zh) * | 2019-06-10 | 2019-08-20 | 南通大学 | 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用 |
-
2019
- 2019-10-25 CN CN201911026232.3A patent/CN110819630B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109897853A (zh) * | 2019-03-13 | 2019-06-18 | 南通大学 | 一种长链非编码rna及其应用 |
CN110141578A (zh) * | 2019-06-10 | 2019-08-20 | 南通大学 | 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用 |
Non-Patent Citations (2)
Title |
---|
Identification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis;Zhou et al.;《Frontiers in Molecular Neuroscience》;20170403;第1-22页 * |
神经干细胞与脊髓损伤修复实验研究进展;白登彦等;《国际骨科学杂志》;20060930;第27卷(第05期);第292-294页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110819630A (zh) | 2020-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106480027A (zh) | CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA | |
CN105524924B (zh) | 环状RNA circ‑ZKSCAN1的用途 | |
CN110819630B (zh) | 环状RNA circ-01477及其应用 | |
Li et al. | Long non-coding RNA LncKdm2b regulates cortical neuronal differentiation by cis-activating Kdm2b | |
WO2018024034A1 (zh) | 环状RNA circ-NFATC3及其用途 | |
CN106701900A (zh) | 长链非编码rna herc2p3基因及其在胃癌中的用途 | |
CN110141578B (zh) | 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用 | |
CN117512087A (zh) | 环状RNA circLRP6在制备中枢神经损伤治疗药物中的应用 | |
CN107557472B (zh) | 胶质瘤诊断标志物circ9:135881633|135883078及应用 | |
CN108531483B (zh) | 一种与椎间盘髓核相关的环状rna及应用 | |
CN112190531B (zh) | 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法 | |
US20230295652A1 (en) | Artificial genome manipulation for gene expression regulation | |
CN114517204B (zh) | 一种用于肿瘤治疗靶点和诊断生物标志物的circPOLK及其应用 | |
CN115786339A (zh) | 一种tmej检测底物、其制备方法及应用 | |
CN109971759A (zh) | circ_ADARB1及其在制备鼻咽癌诊断制剂中的应用和诊断制剂 | |
CN105603117B (zh) | miR-3613用于区分肺鳞癌转移与非转移的miRNA标志物 | |
CN113278690B (zh) | 环状RNA circ-26782在制备脊髓损伤诊疗药物中的应用 | |
EP3943609A1 (en) | Molecular marker detection and regulating methods in de-servitization state of cells | |
CN109852692A (zh) | circ_3480及其在制备鼻咽癌诊断制剂中的应用和诊断试剂 | |
CN112656805A (zh) | 抑制ythdf1活性的物质在制备预防或治疗胃癌产品中的应用 | |
CN109371136A (zh) | 一种与肺腺癌相关的lncRNA及其应用 | |
CN117660300B (zh) | 一种外泌体及cricRNA在糖尿病肾病足细胞损伤中的应用 | |
LU501763B1 (en) | SMALL INTERFERING RNAs (siRNAs) FOR INTERFERING WITH ZINC FINGER PROTEIN 24 (ZNF24) GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION | |
CN104774928B (zh) | 人rrs1基因的应用以及抑制剂 | |
CN112831554B (zh) | 一种SLE相关的环状RNA hsa_circ_0025843及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200221 Assignee: NANTONG EGENS BIOTECHNOLOGY Co.,Ltd. Assignor: NANTONG University Contract record no.: X2023980046726 Denomination of invention: Circular RNA circ-01477 and Its Applications Granted publication date: 20230407 License type: Common License Record date: 20231114 |
|
EE01 | Entry into force of recordation of patent licensing contract |